Trazodone Improves Sleep Parameters in Alzheimer Disease Patients: A Randomized, Double-Blind, and Placebo-Controlled Study
| Autor: | Otávio de Toledo Nóbrega, Luciana L. Louzada, Einstein Francisco Camargos, Juliana Lima Quintas, Fernando Mazzilli Louzada, Janeth de Oliveira Silva Naves |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
Sleep Wake Disorders Placebo-controlled study Comorbidity Placebo law.invention Double-Blind Method Randomized controlled trial Alzheimer Disease law medicine Insomnia Humans Adverse effect Aged Aged 80 and over Therapeutic effect Trazodone Actigraphy Psychiatry and Mental health Treatment Outcome Anesthesia Female Geriatrics and Gerontology medicine.symptom Cognition Disorders Psychology Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | The American Journal of Geriatric Psychiatry. 22:1565-1574 |
| ISSN: | 1064-7481 |
| DOI: | 10.1016/j.jagp.2013.12.174 |
| Popis: | Objectives There are no randomized clinical trials regarding efficacy of trazodone in the treatment of sleep disturbances (SD) in patients with Alzheimer disease (AD). We tested the efficacy and safety of trazodone to treat SD in patients with AD. Design We conducted a double-blind, randomized and controlled trial during periods of 7–9 days at baseline and 2 weeks of treatment. Setting Geriatric medical center of the university's general hospital. Participants Individuals with probable AD and SD. The complete analysis comprised 30 patients assigned to either the active treatment group (N = 15) or the placebo group (N = 15). Intervention Patients received 50 mg of trazodone once daily at 10:00 P.M. or placebo in a 1:1 ratio for 2 weeks. Measurements Patients were evaluated using actigraphy and structured scales before and after intervention. Results Compared with the placebo group, trazodone users slept 42.5 more minutes per night and had their nighttime percent sleep increased 8.5 percentage points according to actigraphic data post-treatment. Neither trazodone nor placebo induced significant daytime sleepiness or naps. The treatments with trazodone or placebo did not show any effects either on cognition (Mini-Mental State Examination, forward/backward digit span task, letter-number sequencing, arithmetic, digit symbol-coding, and symbol search) or functionality (Katz index). There were no differences in frequency or severity rating of adverse events between the groups. Conclusions This study shows significant therapeutic effects of trazodone 50 mg in community-dwelling AD patients with SD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|